Cargando…

Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology. Postmenopausal osteoporosis (PMOP), which increases the risk of fracture, is the most common bone disease in women. PMOP not only increases the risk of death but also impos...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xue, Liang, Jiamin, Wang, Ziyi, Su, Yuangang, Zhan, Yunfei, Wu, Zuoxing, Li, Jing, Li, Xuedong, Chen, Runfeng, Zhao, Jinmin, Xu, Jiake, Liu, Qian, Zhou, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237092/
https://www.ncbi.nlm.nih.gov/pubmed/34194327
http://dx.doi.org/10.3389/fphar.2021.664697
_version_ 1783714662252019712
author Yang, Xue
Liang, Jiamin
Wang, Ziyi
Su, Yuangang
Zhan, Yunfei
Wu, Zuoxing
Li, Jing
Li, Xuedong
Chen, Runfeng
Zhao, Jinmin
Xu, Jiake
Liu, Qian
Zhou, Bo
author_facet Yang, Xue
Liang, Jiamin
Wang, Ziyi
Su, Yuangang
Zhan, Yunfei
Wu, Zuoxing
Li, Jing
Li, Xuedong
Chen, Runfeng
Zhao, Jinmin
Xu, Jiake
Liu, Qian
Zhou, Bo
author_sort Yang, Xue
collection PubMed
description This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology. Postmenopausal osteoporosis (PMOP), which increases the risk of fracture, is the most common bone disease in women. PMOP not only increases the risk of death but also imposes a financial burden on countless families. At present, most of the drugs used to treat osteoporosis have significant side effects, so it is important to find effective anti-osteoporosis medications without major side effects. Sesamolin (Ses) is a kind of natural lignan extracted from sesame oil. Many researches have shown that Ses has anti-inflammatory, antioxidative, and anticancer effects, however it is still unknown whether it has any effect on osteoporosis. In this research, we explored the therapeutic effect of Ses in the process of osteoclast formation and bone resorption and found that Ses effectively inhibited osteoclast formation in vitro through TRAcP staining and hydroxyapatite resorption assays. Through Western blot analysis of the NF-κB pathway, MAPK pathway, c-Fos and NFATc1, it was found that Ses not only effectively inhibited the activation of NF-κB and MAPK signaling pathways induced by RANKL but also significantly reduced the protein expression of c-Fos and NFATc1. Several genes specifically expressed in osteoclasts were determined by qPCR, and Ses was also found to play a significant inhibitory role on the expression of these genes. Besides, an osteoporosis model induced in ovariectomized (OVX) mice was employed to verify that Ses could effectively reduce bone loss caused by estrogen deficiency in vivo. In conclusion, Ses showed promise as a new treatment for postmenopausal osteoporosis.
format Online
Article
Text
id pubmed-8237092
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82370922021-06-29 Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways Yang, Xue Liang, Jiamin Wang, Ziyi Su, Yuangang Zhan, Yunfei Wu, Zuoxing Li, Jing Li, Xuedong Chen, Runfeng Zhao, Jinmin Xu, Jiake Liu, Qian Zhou, Bo Front Pharmacol Pharmacology This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology. Postmenopausal osteoporosis (PMOP), which increases the risk of fracture, is the most common bone disease in women. PMOP not only increases the risk of death but also imposes a financial burden on countless families. At present, most of the drugs used to treat osteoporosis have significant side effects, so it is important to find effective anti-osteoporosis medications without major side effects. Sesamolin (Ses) is a kind of natural lignan extracted from sesame oil. Many researches have shown that Ses has anti-inflammatory, antioxidative, and anticancer effects, however it is still unknown whether it has any effect on osteoporosis. In this research, we explored the therapeutic effect of Ses in the process of osteoclast formation and bone resorption and found that Ses effectively inhibited osteoclast formation in vitro through TRAcP staining and hydroxyapatite resorption assays. Through Western blot analysis of the NF-κB pathway, MAPK pathway, c-Fos and NFATc1, it was found that Ses not only effectively inhibited the activation of NF-κB and MAPK signaling pathways induced by RANKL but also significantly reduced the protein expression of c-Fos and NFATc1. Several genes specifically expressed in osteoclasts were determined by qPCR, and Ses was also found to play a significant inhibitory role on the expression of these genes. Besides, an osteoporosis model induced in ovariectomized (OVX) mice was employed to verify that Ses could effectively reduce bone loss caused by estrogen deficiency in vivo. In conclusion, Ses showed promise as a new treatment for postmenopausal osteoporosis. Frontiers Media S.A. 2021-06-14 /pmc/articles/PMC8237092/ /pubmed/34194327 http://dx.doi.org/10.3389/fphar.2021.664697 Text en Copyright © 2021 Yang, Liang, Wang, Su, Zhan, Wu, Li, Li, Chen, Zhao, Xu, Liu and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yang, Xue
Liang, Jiamin
Wang, Ziyi
Su, Yuangang
Zhan, Yunfei
Wu, Zuoxing
Li, Jing
Li, Xuedong
Chen, Runfeng
Zhao, Jinmin
Xu, Jiake
Liu, Qian
Zhou, Bo
Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
title Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
title_full Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
title_fullStr Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
title_full_unstemmed Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
title_short Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
title_sort sesamolin protects mice from ovariectomized bone loss by inhibiting osteoclastogenesis and rankl-mediated nf-κb and mapk signaling pathways
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237092/
https://www.ncbi.nlm.nih.gov/pubmed/34194327
http://dx.doi.org/10.3389/fphar.2021.664697
work_keys_str_mv AT yangxue sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT liangjiamin sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT wangziyi sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT suyuangang sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT zhanyunfei sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT wuzuoxing sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT lijing sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT lixuedong sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT chenrunfeng sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT zhaojinmin sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT xujiake sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT liuqian sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways
AT zhoubo sesamolinprotectsmicefromovariectomizedbonelossbyinhibitingosteoclastogenesisandranklmediatednfkbandmapksignalingpathways